4th Annual Gene Therapy for Ophthalmic Disorders Summit The Westin Waltham Boston, Waltham

The 4th Annual Gene Therapy for Ophthalmic Disorders Summit is the industry-leading, industry-focused forum for learning how to validate novel administration routes to the eye, extrapolate effectively from preclinical models to inform safety and efficacy and define relevant endpoints for clinical trials.

Across 3 days of in-depth case studies, new data, and focused group discussions, hear from and engage with the likes of Janssen, Adverum Biotechnologies, Spark Therapeutics, SparingVision, AbbVie, and the RD Fund. As well as leveraging insights from these talks and panels: participate in breakout discussions, utilize Q and A time built into talks, and meet and learn from ophthalmic gene therapy leaders during our 5+ hours of dedicated networking time.

This Summit Will Bring Together Leading Voices on:

– Defining Relevant and Meaningful Endpoints
Investigate the latest trends in endpoint development and regulation, understand their applicability in animal model studies to clinical trials, and discuss the need for validated novel endpoints, with key insights from Adverum Biotechnologies and SparingVision.